Categories
Press Release

Adult Malignant Glioma Therapeutics Market Will Exhibit A CAGR of 9.3%; Increasing Cases Of Brain Tumors Will Aid Growth, says Fortune Business Insights

Adult Malignant Glioma Therapeutics MarketIncreasing Prevalence of malignant glioma is a key factor driving the adult malignant glioma therapeutics market, says Fortune Business Insights in a report, titled “Adult Malignant Glioma Therapeutics Market Size, Share and Industry Analysis Product By Therapy (Chemotherapy, Radiotherapy, Targeted therapy) By Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma) By End User, and Regional Forecast 2019-2026.” The global adult malignant glioma therapeutics market size was valued at USD 1,459.1 Million in 2018, is projected to reach USD 2,964.5 Million by the end of 2026, exhibiting a CAGR of 9.3%.

Request a Sample Copy Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/adult-malignant-glioma-therapeutics-market-100572

According to the report, the increasing cases of brain tumors around the world is expected to fuel demand for adult malignant glioma therapeutics. As per, atlasgeneticsoncology.org, gliomas account for 70% of all the brain tumors. Out of which, 65% of were glioblastoma. It also states, around 3% of glioblastoma patients were still alive after 5 years of diagnosis, higher age being the most significant predictor of poor outcome. In addition, during 1992-1997 in the United States, the incidence rate per 100,000 people per year adjusted to 2000 and the incidence rates in Zurich, Switzerland in 1980-1994.

Some of Prominent Companies Operating In Market Are:

  • Merck & Co., Inc.
  • Hoffmann-La Roche Ltd
  • Arbor Pharmaceuticals
  • Pfizer Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/adult-malignant-glioma-therapeutics-market-100572

Government Regulatory Policies Will Favor Growth 

The increasing advancements in imaging technologies have led to early detection of the disease. This factor is expected to accelerate the growth of the market. The regulatory policies and government support for the development of novel therapies is likely to boost the market growth.  The increasing R&D investment by key players for the development of glioma therapies will create growth opportunities for the market. Furthermore, the targeted therapies segment is predicted to account for high shares during the forecast period owing to the advancement in drug development which, results in the successful applications of targeted therapies to improve the survival rate.

Targeted therapies are commonly used in the treatment of gliomas such as EGFR-targeted therapies, which target the tyrosine kinases receptors and others. In terms of end-user, the hospital segment will account for maximum shares during the forecast period owing to the increasing patient population and high hospital admissions

  1. Hoffmann-La Roche Ltd and Merck & Co., Inc. Will Contribute Positively To the Market

Merck & Co., Inc.’s an American multinational pharmaceutical company. One of the leading products of the company is named temodar and internationally as temodal. The company has a well-established footprint across the major markets. Moreover, its strategies to expand in the emerging economies are making the company leader in the glioma therapeutics. F. Hoffmann-La Roche Ltd dominates the adult malignant glioma therapeutics market with its leading product Avastin, approved for the treatment of malignant glioma due to strong clinical pieces of evidence supporting treatment merits.

More Trending Topics from Fortune Business Insights:

US$ 6,875.1 Mn by 2026, Surgical Robots Market Size, Growth 2026 | Prominent Players: Intuitive Surgical Inc., Medtronic, Stryker, Smith & Nephew and Zimmer Biomet & others

Botulinum Toxin Market Size | Top 10 Global Industry Share | CAGR of 8.0 % Forecast 2019 to 2026

Medical Devices Market to Value US$ 602.1 Bn at CAGR of 5.3% by 2025 | Exclusive Report by Fortune Business Insights

Orphan Drugs Market to Reach US$ 294000 Mn by 2025, Increasing Development of Oncology-related Orphan Drugs to Drive the Market: Fortune Business Insights

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: [email protected]

Website: Fortune Business Insights

Follow us on:

LinkedIn | Twitter | Blogs

Leave a Reply

Your email address will not be published. Required fields are marked *